Wednesday, December 15, 2010 10:22:22 AM
Recent studies have found radiosurgery to be an effective treatment option for medically inoperable lung cancer patients as it provides good local control and survival rates. Treating these tumors is particularly complex due to movement with respiration and nearby critical structures. This is especially the case for central and chest wall tumors, which are located in close proximity to such critical anatomical structures.
Lung Optimized Treatment offers the accuracy and steep dose fall off required to safely treat lung tumors, even those close to such critical structures. Simulation and comparison workflows, combined with unique tracking modes, allow the clinician to select from multiple, non-invasive options, providing lung SBRT patients
the optimal non-invasive treatment option, regardless of tumor location.
"Lung Optimized Treatment is a new tool we developed to meet the clinical demand for more flexibility in treating lung cancer patients with radiosurgery and the desire to move away from reliance on fiducial markers," said Chris A. Raanes, senior vice president and chief operating officer for Accuray. "This new technology
enables treatments throughout the lung without a single incision, all while safeguarding healthy tissue and structures around the tumor to ensure they are not damaged by radiation."
Because fiducial implantation is no longer required, CyberKnife radiosurgery with Lung Optimized Treatment offers a completely non-invasive option, which is particularly important for medically or surgically inoperable patients. This means patients who are not candidates for fiducial placement or physicians who choose not to implant fiducials due to the high risk of pneumothorax, now have a non-invasive alternative using the CyberKnife System's unique tracking and correction capabilities.
"With the FDA 510(k) clearance of Lung Optimized Treatment, we've taken the CyberKnife technology to new heights and enabled care for an expanded group of patients," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "This is yet another step in our efforts to ensure physicians have access to the treatment choices necessary for their patient, based on the patient's specific needs. To this end, Accuray continues to investigate ways to improve patient care across various indications."
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
Recent ARAY News
- Accuray Reports Fiscal 2024 Third Quarter Financial Results • PR Newswire (US) • 05/01/2024 08:06:00 PM
- Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 • PR Newswire (US) • 04/25/2024 11:35:00 AM
- Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland • PR Newswire (US) • 04/18/2024 11:35:00 AM
- Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024 • PR Newswire (US) • 04/17/2024 08:05:00 PM
- New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System • PR Newswire (US) • 03/26/2024 11:35:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:15:22 PM
- Accuray Incorporated to Speak at 36th Annual Roth Conference • PR Newswire (US) • 03/04/2024 09:30:00 PM
- Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference • PR Newswire (US) • 02/27/2024 10:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 04:19:22 PM
- Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System • PR Newswire (US) • 02/13/2024 12:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 08:01:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:15:46 PM
- Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference • PR Newswire (US) • 02/05/2024 10:30:00 PM
- Accuray Reports Fiscal 2024 Second Quarter Financial Results • PR Newswire (US) • 01/31/2024 09:06:00 PM
- Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions • PR Newswire (US) • 01/25/2024 12:35:00 PM
- Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024 • PR Newswire (US) • 01/16/2024 10:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:15:14 PM
- Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System • PR Newswire (US) • 12/05/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:51:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:50:37 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM